Spin-off Company Forms to Advance Potential Cancer Treatment

Post Date: May 1, 2020


Daniel Starczynowski, PhD

Seed investor CincyTech has announced the formation of Kurome Therapeutics (“Kurome”), a spin-off company based on cancer research discoveries made at Cincinnati Children’s by Daniel Starczynowski, PhD, and colleagues.

Kurome is developing combined IRAK1/4 and panFLT3 inhibitors to target cancer cells that evade the effects of chemotherapy drugs by adaptive resistance, having co-opted immune signaling pathways to survive.

Read more from CincyTech

Read more about this line of research:

NIH, Cincinnati Children’s Scientists Develop Potential Strategy Against Leukemia Drug Resistance

Overlooked Molecular Machine in Cell Nucleus May Hold Key to Treating Aggressive Leukemia

Science Translational Medicine: Overcoming adaptive therapy resistance in AML by targeting immune response pathways